Rising Pharmaceuticals debuts generic Canasa

BY Sandra Levy

Rising Pharmaceuticals is debuting its generic Canasa (mesalamine suppositories). The generic version of Allergan’s branded drug is indicated to treat mild-to-moderately active ulcerative proctitis. It will be available in 1,000-mg strength.

“We’re pleased to add to our portfolio of generic medicines a valued treatment option for people living with mildly to moderately active ulcerative proctitis,” Ira Baeringer, Rising Pharmaceuticals chief operating officer said.

Mesalamine suppositories had a market value of roughly $263 million for the 12 months ended March 2019, according to IQVIA.




Leave a Reply

No comments found



What area is your company focused most on in 2019?
  • Add your answer